Tuesday 22 April 2014

AstraZeneca cancer pipeline seen as draw for Pfizer

Pedestrians walk past the world headquarters of Pfizer in New York By Ben Hirschler LONDON (Reuters) - Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise. In addition to adding promising - though still risky - experimental medicines known as immunotherapy's that boost the body's immune system to fight tumors, acquiring AstraZeneca could also generate significant cost savings, according to industry analysts. As a result, a deal at around a 25 percent premium to the current share price funded by cash, cheap debt and some stock could boost Pfizer earnings immediately, they believe. Both companies have declined to comment on a report in the Sunday Times, which cited senior investment bankers and industry sources saying that Pfizer approached the British pharmaceuticals group about a deal.




via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment